Telix Pharmaceuticals Limited (TLX) Discusses Advances in PSMA Therapy and Insights from the OPTIMAL-PSMA Trial with TLX597 Transcript
Telix Pharmaceuticals Limited discussed recent advances in PSMA-targeted therapy and shared insights from the ongoing OPTIMAL-PSMA trial involving its investigational agent TLX597. The company highlighted the potential of its next-generation radiopharmaceuticals in improving outcomes for patients with prostate cancer. These developments were presented in a transcript of a conference call held on April 29, 2026.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4896427-telix-pharmaceuticals-limited-tlx-discusses-advances-in-psma-therapy-and-insights-from-the"},"author":{"@type":"Person","name":"SA Transcripts","url":"https://seekingalpha.com/author/sa-transcripts"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New York","addressRegion":"NY","postalCode":"10001","addressCountry":"US"},"alternateName":["SeekingAlpha","SA"],"brand":[{"@type":"Brand","name":"Seeking Alpha Premium","url":"https://seekingalpha.com/subscriptions/premium"},{"@type":"Brand","name":"Seeking Alpha…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
